ACADIA Pharmaceuticals Inc.

22.60+0.3200+1.44%Vol 1.18M1Y Perf 45.24%
Dec 1st, 2023 16:00 DELAYED
BID22.47 ASK22.89
Open22.35 Previous Close22.28
Pre-Market- After-Market22.48
 - -  -0.12 -0.53%
Target Price
18.47 
Analyst Rating
Moderate Buy 2.00
Potential %
-18.27 
Finscreener Ranking
★★★     48.90
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★+     49.24
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★+     49.46
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
41.71 
Earnings Rating
Strong Buy
Market Cap3.71B 
Earnings Date
2nd Nov 2023
Alpha0.01 Standard Deviation0.14
Beta0.62 

Today's Price Range

22.0722.76

52W Range

14.4533.99

5 Year PE Ratio Range

-18.80-14.00

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-0.04%
1 Month
-2.79%
3 Months
-19.83%
6 Months
-6.78%
1 Year
45.24%
3 Years
-60.77%
5 Years
16.89%
10 Years
-4.34%

TickerPriceChg.Chg.%
ACAD22.600.32001.44
AAPL191.241.29000.68
GOOG133.32-0.6000-0.45
MSFT374.51-4.4000-1.16
XOM102.990.25000.24
WFC45.020.43000.96
JNJ158.383.72002.41
FB196.640.99000.51
GE122.500.70000.57
JPM156.840.76000.49
Financial StrengthValueIndustryS&P 500US Markets
4.20
4.50
0.11
0.13
-
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
98.00
-43.40
-43.00
-101.10
-45.77
RevenueValueIndustryS&P 500US Markets
380.75M
2.35
22.93
56.36
Earnings HistoryEstimateReportedSurprise %
Q03 2023-0.43-0.406.98
Q02 2023-0.120.01108.33
Q01 2023-0.21-0.27-28.57
Q04 2022-0.25-0.26-4.00
Q03 2022-0.18-0.175.56
Q02 2022-0.25-0.2116.00
Q01 2022-0.49-0.70-42.86
Q04 2021-0.24-0.27-12.50
Earnings Per EndEstimateRevision %Trend
12/2023 QR0.3317.86Positive
12/2023 FY-0.3319.51Positive
3/2024 QR0.21162.50Positive
12/2024 FY0.9480.77Positive
Next Report Date-
Estimated EPS Next Report-0.43
Estimates Count10
EPS Growth Next 5 Years %43.40
Volume Overview
Volume1.18M
Shares Outstanding164.18K
Shares Float119.03M
Trades Count14.76K
Dollar Volume26.49M
Avg. Volume1.22M
Avg. Weekly Volume882.93K
Avg. Monthly Volume1.26M
Avg. Quarterly Volume1.51M

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) stock closed at 22.28 per share at the end of the most recent trading day (a 0.68% change compared to the prior day closing price) with a volume of 1.34M shares and market capitalization of 3.71B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 580 people. ACADIA Pharmaceuticals Inc. CEO is Stephen R. Davis.

The one-year performance of ACADIA Pharmaceuticals Inc. stock is 45.24%, while year-to-date (YTD) performance is 39.95%. ACAD stock has a five-year performance of 16.89%. Its 52-week range is between 14.45 and 33.99, which gives ACAD stock a 52-week price range ratio of 41.71%

ACADIA Pharmaceuticals Inc. currently has a PE ratio of -12.80, a price-to-book (PB) ratio of 6.58, a price-to-sale (PS) ratio of 7.17, a price to cashflow ratio of -, a PEG ratio of -0.29, a ROA of -29.57%, a ROC of -39.09% and a ROE of -39.13%. The company’s profit margin is -45.77%, its EBITDA margin is -43.00%, and its revenue ttm is $380.74 Million , which makes it $2.35 revenue per share.

Of the last four earnings reports from ACADIA Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.43 for the next earnings report. ACADIA Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for ACADIA Pharmaceuticals Inc. is Moderate Buy (2), with a target price of $18.47, which is -18.27% compared to the current price. The earnings rating for ACADIA Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ACADIA Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ACADIA Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 20.16, ATR14 : 0.77, CCI20 : -52.46, Chaikin Money Flow : 0.09, MACD : -0.23, Money Flow Index : 52.78, ROC : 0.36, RSI : 46.48, STOCH (14,3) : 38.67, STOCH RSI : 0.99, UO : 52.00, Williams %R : -61.33), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ACADIA Pharmaceuticals Inc. in the last 12-months were: Austin D. Kim (Option Excercise at a value of $0), Austin D. Kim (Sold 1 392 shares of value $25 170 ), Baker Julian (Option Excercise at a value of $78 300), Brendan P. Teehan (Option Excercise at a value of $0), Brendan P. Teehan (Sold 993 shares of value $17 771 ), Daniel Soland (Option Excercise at a value of $0), Davis Stephen (Option Excercise at a value of $0), Davis Stephen (Sold 75 706 shares of value $1 592 701 ), Edmund P. Harrigan (Option Excercise at a value of $0), Garofalo Elizabeth (Option Excercise at a value of $0), James Daly (Option Excercise at a value of $0), James K. Kihara (Option Excercise at a value of $0), James K. Kihara (Sold 350 shares of value $6 573 ), James Kihara (Sold 0 shares of value $0 ), James Kihara (Sold 13 506 shares of value $307 598 ), Kim Austin (Option Excercise at a value of $0), Kim Austin (Sold 20 134 shares of value $430 496 ), Laura A. Brege (Option Excercise at a value of $212 625), Laura A. Brege (Sold 12 500 shares of value $228 125 ), Laura Brege (Option Excercise at a value of $212 625), Laura Brege (Sold 4 500 shares of value $111 915 ), Mark C. Schneyer (Option Excercise at a value of $0), Mark C. Schneyer (Sold 577 shares of value $10 836 ), Ndu Adora (Sold 0 shares of value $0 ), Schneyer Mark (Sold 0 shares of value $0 ), Schneyer Mark (Sold 33 885 shares of value $820 120 ), Schneyer Mark C. (Option Exercise at a value of $0), Schneyer Mark C. (Sold 974 shares of value $24 369 ), Stephen R. Davis (Option Excercise at a value of $0), Stephen R. Davis (Sold 7 755 shares of value $139 198 ), Teehan Brendan (Option Excercise at a value of $0), Teehan Brendan (Sold 23 121 shares of value $508 022 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
9 (52.94 %)
9 (52.94 %)
7 (41.18 %)
Moderate Buy
1 (5.88 %)
1 (5.88 %)
1 (5.88 %)
Hold
6 (35.29 %)
6 (35.29 %)
8 (47.06 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (5.88 %)
1 (5.88 %)
1 (5.88 %)
Summary RatingModerate Buy
2.00
Moderate Buy
2.00
Moderate Buy
2.24

ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

CEO: Stephen R. Davis

Telephone: +1 858 558-2871

Address: 12830 El Camino Real, San Diego 92130, CA, US

Number of employees: 580

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

58%42%

Bearish Bullish

61%39%

Bearish Bullish

55%45%

 

News

Stocktwits